RiverVest Venture Partners is a venture capital firm based in St. Louis, Missouri, that builds and invests in early-stage life science companies, focusing on biopharmaceuticals and medical devices. Founded in 2000, the firm has raised over $1.6 billion in total assets under management across five funds, with its latest fund (RiverVest Venture Fund V) closing at $275 million in March 2021.
35% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 4 prior). Their most common stage is series-b (42% of deals). Average disclosed round size is $65.1M (across 65 rounds with reported amounts).
Portfolio
48
Fund Size
$275M
Top Stage
Series B
Last 12 Mo
2
Team
Kelly Cathey
Director of Administration
Nafise Masoumi
Principal
Jeff Seitz
Senior Analyst
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Sparrow Pharmaceuticals | Series B | $95M | Sep 2025 |
| SSparrow Pharma | Series B | $95M | Sep 2025 |
 Wugen | Series B | $115M | Aug 2025 |
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
 Reneo | Series B | $47.3M | Feb 2025 |
 Atalanta Therapeutics | Series B | $75M | Jan 2025 |
 Glycomine, Inc. | Series C | $115M | Jan 2025 |
| Wugen | Series A | $115M | Jan 2025 |
| BBluejay Therapeutics | Series C | $182M | May 2024 |
 Engrail Therapeutics | Series B | $157M | Mar 2024 |
| EEngrail | Series B | $157M | Mar 2024 |
| Avalyn Pharma, Inc. | Series C | $175M | Sep 2023 |
| AAvalyn | Series C | $100M | Sep 2023 |
 OncoResponse | Series D | $13M | May 2023 |
 OncoResponse, Inc. | Unknown | $13M | Jan 2023 |
| Avalyn Pharma, Inc. | Series C | $175M | Jan 2023 |
| BBluejay Therapeutics | Series B | $41M | Aug 2022 |
 Good Therapeutics | Series B | $8M | Dec 2021 |
| SStandard Bariatrics, Inc. | Series B | $35M | Jun 2021 |
| Sparrow Pharmaceuticals | Series A | $50M | May 2021 |
 Arch Oncology, Inc. | Series C | $105M | Apr 2021 |
| OncoResponse, Inc. | Series C | $40.6M | Jan 2021 |
| OncoResponse | Series C | $40.6M | Jan 2021 |
| Wugen | Series B | $172M | Jan 2021 |
| RReneo Pharmaceuticals Inc | Series B | $95M | Dec 2020 |
Top Co-Investors
Last updated: 7 October 2026